Multimodal, multiclass prediction of disease status in Alzheimer’s
Multimodal, multiclass prediction of disease status in Alzheimer’s
批准号:
10538418
负责人:
Yueqi Ren
金额:
$4.22万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-01 至 2026-08-31
关键词:
AddressAffectAgingAlzheimer disease detectionAlzheimer&aposs DiseaseAlzheimer&aposs disease diagnosisAlzheimer&aposs disease related dementiaAlzheimer&aposs disease riskAlzheimer’s disease biomarkerAmericanAmyloidAmyloid beta-ProteinApolipoprotein EAreaBehavioralBiological MarkersCaliforniaClassificationClinicalClinical TreatmentClinical TrialsCognitionCommunitiesDataData ScienceData SetDementiaDetectionDevelopmentDiagnosisDifferential DiagnosisDiseaseDisease ProgressionEarly DiagnosisElderlyEnvironmentFamily CaregiverFellowshipFundingGenotypeGoalsInstitutionJointsKnowledgeLassoMachine LearningMagnetic Resonance ImagingMentorshipMeta-AnalysisMethodsModalityModelingNatureOutcomePathologyPhysiciansPositron-Emission TomographyPublic HealthQuality of lifeResearchRiskScientistSignal TransductionTechniquesTherapeuticTrainingUniversitiesValidationWorkcareerclinical biomarkersclinical diagnosisclinical practiceclinical predictorsdata fusiondesigndisorder riskexperimental studyimprovedinsightlarge datasetsmachine learning classifiermachine learning modelmild cognitive impairmentmultimodal datamultimodalityneuroimagingneuropsychiatryoutcome predictionpatient stratificationpredictive modelingrandom forestscreeningstatistical and machine learningstatisticstau Proteinstherapy developmenttherapy outcome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
As the number of Americans living with Alzheimer’s disease (AD) is projected to reach 13 million by 2050, we
must prioritize efforts for early disease detection. The bottleneck of early AD detection has greatly hindered
clinical treatment and development of successful therapeutics. With greater availability of multimodal AD
biomarkers in clinical practice, we have a unique opportunity to leverage statistical machine learning for earlier
detection of AD. Past work has demonstrated good classification accuracy of clinical diagnosis of AD using
binary classifications (i.e., AD-dementia vs healthy cognition, HC; mild cognitive impairment, MCI vs HC; AD vs
MCI). These classifiers, however, are often reliant on unimodal biomarker inputs, and no formal comparison of
multimodal biomarker integration (“fusion”) methods exist for predicting either AD clinical diagnosis or
biomarker status as defined by the A/T(N) framework. Lack of optimal multimodal fusion strategies and holistic
diagnosis prediction beyond binary classification reduce the translational value of statistical machine learning
classifiers in clinical practice. This proposal fills these gaps by evaluating several competing strategies for
multimodal fusion and multiclass classification (e.g., AD vs MCI vs HC) using data from the National
Alzheimer’s Coordinating Center and Alzheimer’s Disease Neuroimaging Initiative. The strength of using large,
multimodal datasets for disease prediction is accompanied by the challenge of handling missing data, a barrier
for building a reliable classifier. This proposal will address these challenges with two specific aims: (1) compare
techniques for optimal data imputation and multimodal fusion, and (2) develop a multiclass model to accurately
predict AD status (AD/MCI/HC and A+T+/A+T-/A-T-) using multimodal inputs. Preliminary analyses of
multimodal data fusion in binary classification using random forest and sparse group lasso classifiers motivate
Aim 1. Preliminary analysis of two strategies of multiclass classification demonstrates feasibility of developing a
multimodal, multiclass classifier for Aim 2. The proposed work will be enhanced by the excellent training and
research environment at the University of California, Irvine (UCI), including direct access to 1 of 33 NIA-funded
Alzheimer’s Disease Research Centers (ADRCs). The ADRC offers a third, independent dataset to serve as a
validation set to improve the rigor of results from the proposed experiments. The applicant will be supported by
the joint mentorship of Dr. Craig Stark, the ADRC Biomarker Core Leader, and Dr. Babak Shahbaba, Director
of the UCI Data Science Initiative, and will receive advanced training in both aging and AD research and
statistics and machine learning techniques. Fellowship training will be further strengthened by the additional
mentorship of Dr. Peter Chang for machine learning, Dr. Michele Guindani for multimodal data fusion, and Dr.
S. Ahmad Sajjadi for clinical expertise in AD. The proposed training and research plans will result in the
development of a reliable, multimodal, and multiclass classifier for AD status prediction to enable earlier
disease detection and stratification of patients for more effective clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Multimodal, multiclass prediction of disease status in Alzheimer’s
-
批准号:10730543
-
项目类别:
-
资助金额:$4.39万
-
财政年份:2022
-
负责人:Yueqi Ren
-
依托单位:
海外基金